Literature DB >> 2804344

Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A.

F Rodeghiero1, G Castaman, E Di Bona, M Ruggeri.   

Abstract

The consistency in time of responses to separate desmopressin (DDAVP) infusions in patients with von Willebrand's disease (vWD) and mild or moderate hemophilia A has been the subject of limited investigation. We report here the results of a clinical study undertaken to test the consistency of responses to repeated DDAVP administrations in 22 patients with vWD and 10 with mild or moderate hemophilia A (time interval between first and last infusion ranging from 1 to 77 months; median, 13 months). In patients with vWD, 80% of cases showed a departure of less than 20% from the average VIII:C peak level calculated after the two infusions. A similarly consistent pattern was observed for bleeding times recorded 30 minutes after each infusion. In patients with hemophilia A, some infused on more than two instances, the departure from the average VIII:C peak level was less than 20% in nearly 70% of cases. A good within-family consistency was also demonstrated by analyzing data obtained from seven kindreds with vWD and two with hemophilia A. In conclusion, our study suggests that the pattern of responsiveness observed after a DDAVP test-infusion can be reliably used to decide the future clinical management of the individual patient and that a similar pattern of response is usually observed within the same kindred.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804344

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Current management of von Willebrand's disease.

Authors:  G Castaman; F Rodeghiero
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

2.  Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.

Authors: 
Journal:  CMAJ       Date:  1995-07-15       Impact factor: 8.262

3.  von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.

Authors:  Ferdows Atiq; Lisette M Schütte; Agnes E M Looijen; Johan Boender; Marjon H Cnossen; Jeroen Eikenboom; Moniek P M de Maat; Marieke J H A Kruip; Frank W G Leebeek
Journal:  Blood Adv       Date:  2019-12-23

Review 4.  Principles of care for the diagnosis and treatment of von Willebrand disease.

Authors:  Giancarlo Castaman; Anne Goodeve; Jeroen Eikenboom
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

Review 5.  Current and Emerging Options for the Management of Inherited von Willebrand Disease.

Authors:  Jessica M Heijdra; Marjon H Cnossen; Frank W G Leebeek
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

6.  Desmopressin in moderate hemophilia A patients: a treatment worth considering.

Authors:  Janneke I Loomans; Marieke J H A Kruip; Manuel Carcao; Shannon Jackson; Alice S van Velzen; Marjolein Peters; Elena Santagostino; Helen Platokouki; Erik Beckers; Jan Voorberg; Johanna G van der Bom; Karin Fijnvandraat
Journal:  Haematologica       Date:  2018-01-05       Impact factor: 9.941

7.  Desmopressin testing in von Willebrand disease: Lowering the burden.

Authors:  Jessica M Heijdra; Ferdows Atiq; Wala Al Arashi; Quincy Kieboom; Esmee Wuijster; Karina Meijer; Marieke J H A Kruip; Frank W G Leebeek; Marjon H Cnossen
Journal:  Res Pract Thromb Haemost       Date:  2022-09-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.